ADIL
ADIAL PHARMACEUTICALS, INC.
기간
1.43 USD
최근 종가 · 사전계산값
- PER (TTM)
- -
- PER (Forward)
- -0.55
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- 0.30
- 시가총액
- 2.04M
- 배당수익률
- -
- 베타
- 1.27
- 1개월 수익률
- -8.33%
- 3개월 수익률
- -54.17%
- 6개월 수익률
- -82.67%
- 1년 수익률
- -91.20%
- 2년 수익률
- -
- 5일 평균거래량
- 130120
- 60일 평균거래량
- 115542
- 1년 평균거래량
- 129214
- 5d/60d 거래량 비율
- 1.13×
- 60d/1y 거래량 비율
- 0.89×
- 변동성(60일, 연환산)
- 72.43%
- BB 스퀴즈 스코어
- 0.22
- SMA50 비율
- 0.82
- SMA200 비율
- 0.23
- RSI (14)
- 30
- 20일 수렴도
- 0.03
- 52주 최고
- 18.25
- 52주 최저
- 1.42
- 고점 대비
- -92.16%
- 저점 대비
- 0.70%
펀더멘털 갱신: 2026-05-10T07:29:52+00:00 · 시세 갱신: 2026-05-10T06:07:39+00:00
회사 정보
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.